ARX 2002

Drug Profile

ARX 2002

Latest Information Update: 08 Feb 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AlphaRx
  • Class Anti-inflammatories
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

Most Recent Events

  • 08 Feb 2005 Discontinued - Preclinical for Neuroprotection in Canada (unspecified route)
  • 22 Oct 2002 Preclinical data from a media release have been added to the Neuroprotection/Inflammation pharmacodynamics section
  • 08 Nov 2001 Preclinical development for Neuroprotection/Inflammation (prevention) in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top